Seres Therapeutics (MCRB) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one ...

A downtrend has been apparent in Seres Therapeutics (MCRB) lately. While the stock has lost 32.6% over the past two weeks, it could witness a trend reversal as a hammer chart pattern was formed in ...

Seres Therapeutics MCRB shares soared 5.8% in the last trading session to close at $6.05. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Chardan Capital analyst Keay Nakae reiterated a Buy rating on Seres Therapeutics (MCRB – Research Report) yesterday and set a price target of $10.00. The company’s shares closed yesterday at ...

TD Cowen analyst Joseph Thome maintained a Buy rating on Seres Therapeutics (MCRB – Research Report) yesterday. The company’s shares closed yesterday at $1.06. According to TipRanks, Thome is ...